Completed PHASE1 INTERVENTIONAL 1-arm NCT05763459

A Phase 1 Study of ABBV-CLS-7262, Rosuvastatin, and Digoxin in Healthy Subjects

A Phase 1 Study to Evaluate the Drug-Drug Interaction Between ABBV-CLS-7262, Rosuvastatin, and Digoxin Following Multiple Doses of ABBV-CLS-7262

Sponsor: AbbVie

Conditions Healthy

Interventions ABBV-CLS-7262

Updated 6 times since 2023 Last updated: Jun 23, 2023 Started: Mar 24, 2023 Primary completion: May 8, 2023 Completion: Jun 2, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Healthy and is currently completed. AbbVie leads this study, which shows 6 recorded versions since 2023 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jul 2023 — Jul 2024 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Jun 2023 — Jul 2023 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
May 2023 — Jun 2023 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Apr 2023 — May 2023 [monthly]

Not Yet Recruiting PHASE1

First recorded

Mar 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AbbVie
Calico Life Sciences LLC

Data source: Calico Life Sciences LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Grayslake, United States